

## CONTENTS

Sl. no.	List of headings	Page no.
1.	<b>Acknowledgement</b>	ix
2.	<b>Abstract</b>	xi
3.	<b>List of symbols</b>	xiii
4.	<b>List of abbreviations</b>	xiv
5.	<b>List of figures</b>	xvii
6.	<b>List of tables</b>	xix
7.	<b>CHAPTER I: INTRODUCTION</b>	1
	1.1. Sepsis	1
	1.1.1 Epidemiology	1
	1.1.2. Clinical features of sepsis	1
	1.1.3. Pathogenesis of sepsis	2
	1.1.4. Management of sepsis	4
	1.1.5. Complication of sepsis	4
	1.2. Septic arthritis	5
	1.2.1. Epidemiology	5
	1.2.2. Clinical features of septic arthritis	5
	1.2.3. Pathogenesis of septic arthritis	6
	1.2.4. Management of septic arthritis	7
	1.2.4. Complication of septic arthritis	7
	1.3. <i>Staphylococcus aureus</i>	7
	1.3.1. Morphology	7
	1.3.2. Biochemical characteristics	7
	1.3.3. <i>S. aureus</i> infection	10
	1.3.4. Incidences of <i>S. aureus</i> infection	12
	1.3.5. Current line of management and challenges in treating <i>S. aureus</i> infection	12
	1.3.6. Role of <i>S. aureus</i> in sepsis	15
	1.3.7. Role of <i>S. aureus</i> in septic arthritis	15

	1.4. <i>S. aureus</i> cell wall: important virulence factor in sepsis and septic arthritis	16
	1.4.1 Teichoic acid	16
	1.4.2. <i>O</i> -acetylation of bacterial peptidoglycan	17
	1.5. Evasion mechanisms of <i>S. aureus</i> against host immune response	19
	1.6. Role of lysozyme in host immune response	19
	1.6.1. <i>S. aureus</i> sensitivity to lysozyme	24
	1.6.2. <i>O</i> -acetyl transferase-major determinant of lysozyme resistance	24
	1.7. <i>In vivo</i> models to study <i>S. aureus</i> infection	27
	1.7.1. <i>Drosophila melanogaster</i> model of <i>S. aureus</i> infection	27
	1.7.2. Murine mode of sepsis	27
	1.7.3. Murine mode of septic arthritis	28
	1.8. Current deficit	28
8.	Hypothesis	29
9.	<b>CHAPTER II: MATERIALS AND METHODS</b>	30
	2.1. Materials	30
	2.1.1. Chemicals and reagents	30
	2.1.2. Bacterial strains and plasmids	30
	2.1.3. Consumables	30
	2.1.4. Instruments	30
	2.1.5. Assay kits	32
	2.2. Methods	33
	2.2.1. Bacterial culture	33
	2.2.2. Bacterial growth curve of SA113 and $\Delta oatA$ in presence or absence of lysozyme	33
	2.2.3. Bacterial survival assays/ Lysozyme induced lysis assay	33
	2.2.4. Scanning electron microscopy: <i>S. aureus</i> and <i>S. carnosus</i>	34
	2.2.5. Survival of <i>S. aureus</i> strains in human whole blood and human synovial fluid	34
	2.2.6. Intracellular survival in macrophages and endothelial cells	34

	2.3. <i>Drosophila melanogaster</i> strains and maintenance	35
	2.3.1. Fly infection	35
	2.3.2. Fly survival	35
	2.3.3. Rapid iterative negative geotaxis (RING)	36
	2.4. Murine model of sepsis and septic arthritis	36
	2.4.1. Mice	36
	2.4.2. Determination of the fitness of SA113 and $\Delta oatA$ in murine model of bacterial sepsis	36
	2.4.3. Histopathology	37
	2.4.4. Mouse model for hematogenous <i>S. aureus</i> arthritis	38
	2.4.5. Mice model of local septic arthritis	38
	2.4.6. Body weight and knee swelling measurement	39
	2.4.7. Extensor posterior thrust analysis (EPT)	39
	2.4.8. Locomotion pattern estimation using open-field test arena	39
	2.4.9. Clinical scoring of arthritis	40
	2.4.10. Bacterial load estimation in the knee joint	40
	2.4.11. Radiology	40
	2.4.12. Joint cytokine measurements (ELISA)	40
	2.4.13. Development of anti-lysozyme antibody	41
	2.4.14. Binding of lysozyme with cell wall	41
	2.4.15. Survival of wild type <i>S. aureus</i> in presence of anti-lysozyme antibody in human blood	41
	2.4.16. Ethics statement	42
	2.4.17. Statistical analysis	42
10.	<b>CHAPTER III: RESULTS AND DISCUSSION</b>	43
	<b>3.1. Cell wall peptidoglycan O-acetylation of <i>S. aureus</i> and lysozyme sensitivity</b>	43
	3.1.1. Results	43
	3.1.1.1. Decreased growth of $\Delta oatA$ in comparison with SA113 and complemented strain in presence of lysozyme	43

3.1.1.2. Decreased survival rate of $\Delta oatA$ in comparison with SA113 and complemented strain in presence of lysozyme	45
3.1.1.3. SEM imaging showed structural deformation in $\Delta oatA$ cells while SA113 cells remained morphologically intact	47
3.1.1.4. SEM imaging of <i>S. carnosus</i> showed resistance towards lysozyme action with overexpression of <i>oatA</i>	49
3.1.1.5. Diminished growth rate of $\Delta oatA$ cells in human blood when compared with wild type SA113 or complemented strain	51
3.1.1.6. Reduced growth rate of $\Delta oatA$ cells in human synovial fluid when compared with SA113	51
3.1.1.7. Geimsa staining showed $\Delta oatA$ cells had a lower survival rate in human blood samples when compared with wild type SA113 or complemented strain	53
3.1.1.8. Decreased survival rate of $\Delta oatA$ while sustained SA113 growth intracellular in macrophages	55
3.1.1.9. Quantification of the lysozyme content in human synovial fluid using anti lysozyme antibody	57
3.1.1.10. Enhanced survival rate of $\Delta oatA$ in presence of anti-lysozyme antibody in human blood	59
3.1.2. Discussion	61
3.1.3. Conclusion	63
<b>3.2. Peptidoglycan O-acetylation of <i>S. aureus</i> cell wall &amp; pathogenesis in different infection models</b>	65
3.2.1. Results	65
3.2.1.1. $\Delta oatA$ infected <i>Drosophila melanogaster</i> showed higher survival rate and functionality than SA113 infected flies	65
3.2.1.2. Severity of the sepsis were significantly decreased in $\Delta oatA$ mutant infected mice than SA113 infected mice	67
3.2.1.3. Renal abscess evaluation showed lesser organ damage in $\Delta oatA$ mutant infected mice than SA113 infected mice	69

	3.2.1.4. $\Delta oatA$ is less arthritogenic in hematogenous <i>S. aureus</i> arthritis model	71
	3.2.1.5. Micro CT images showed less bone damage due to $\Delta oatA$ in hematogenous <i>S. aureus</i> arthritis model	73
	3.2.1.6. Severity of the clinical arthritis was significantly lower in $\Delta oatA$ strain infected mice in a localized model of septic arthritis	75
	3.2.1.7. Behavioral analysis of the clinical arthritis showed significantly higher motor strength and locomotry behavior in $\Delta oatA$ infected mice	77
	3.2.1.8. Articular tissue damage and bacterial load was reduced in $\Delta oatA$ inoculated mice	79
	3.2.1.9. Reduced inflammatory cytokines in knees exposed to $\Delta oatA$ mutant strain	81
	3.2. Discussion	83
	3.3. Conclusion	86
11.	<b>CHAPTER IV: SUMMARY</b>	87
12.	<b>CHAPTER V: REFERENCES</b>	88
13.	<b>LIST OF PUBLICATIONS</b>	103